MUSTARGEN POWDER FOR SOLUTION
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
11-09-2009
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
MECHLORETHAMINE HYDROCHLORIDE
Fáanlegur frá:
LUNDBECK PHARMACEUTICALS LLC
ATC númer:
L01AA05
INN (Alþjóðlegt nafn):
CHLORMETHINE
Skammtar:
10MG
Lyfjaform:
POWDER FOR SOLUTION
Samsetning:
MECHLORETHAMINE HYDROCHLORIDE 10MG
Stjórnsýsluleið:
INTRAVENOUS
Einingar í pakka:
10MG VIAL
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ANTINEOPLASTIC AGENTS
Vörulýsing:
Active ingredient group (AIG) number: 0152196001; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2011-11-11
Vara einkenni
PAGE 1 OF 17
PRODUCT MONOGRAPH
TRITURATION OF
MUSTARGEN
®
mechlorethamine HCl for injection USP
Sterile vial for injection containing 10 mg mechlorethamine
hydrochloride
Alkylating Agent
Lundbeck Inc.
Date of Preparation:
Four Parkway North
September 11, 2009
Deerfield, IL 60015, U.S.A
CONTROL # 132246
PAGE 2 OF 17
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
..............................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................
4
ADVERSE REACTIONS
.............................................................................................
6
DRUG INTERACTIONS
..............................................................................................
8
DOSAGE AND
ADMINISTRATION.............................................................................
8
OVERDOSAGE.........................................................................................................
10
PART II: SCIENTIFIC INFORMATION
.........................................................................
10
ACTION AND CLINICAL
PHARMACOLOGY............................................................
10
STORAGE AND STABILITY
.....................................................................................
10
SPECIAL HANDLING
INSTRUCTIONS....................................................................
11
DOSAGE FORMS, COMPOSITION AND
PACKAGING........................................... 11
PHARMACEUTICAL INFORMATION
.......................................................................
11
REFERENCES..........................................................................................................
12
PART III: C
Lestu allt skjalið
